Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Regeneron Pharmaceuticals (NQ: REGN )

1,177.23 +1.90 (+0.16%)
Streaming Delayed Price Updated: 12:35 PM EDT, Aug 16, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Regeneron Pharmaceuticals

< Previous 1 2
...
6 7 8 9 10 11 12 13 14
...
33 34 Next >
Regeneron's Crucial Eylea HD Approval: A Shield Against Potential Biosimilar Competition?
Friday, the FDA approved Regeneron Pharmaceuticals Inc's (NASDAQ: REGN) approved Eylea HD (aflibercept) Injection 8 mg for wet age-related macular degeneration, diabetic macular edema,  
Via Benzinga
Exposures Product Safety
Value Stocks Outshine Growth Amidst Rising Treasury Yields: Key Sectors and Stocks Analyzed
The Vanguard Value Index Fund ETF (ARCA: VTV) has beaten the Vanguard Growth Index Fund ETF (ARCA: VUG) by 5% during the past month. The momentum shift comes as investors recalibrate their strategies... 
Via Benzinga
Topics ETFs
Large Cap Biopharmaceuticals Performance 2023 YTD: Mixed Results But Lilly Is A Big Winner
Biotech stocks are in a bear market since the IBB hit $177.37 in 2021 and is down 7.84% over five years. 
Via Talk Markets
FDA Approves Regeneron's Drug For Ultra Rare Immune Disorder
The FDA approved  Regeneron Pharmaceuticals Inc's (NASDAQ: REGN) Veopoz (pozelimab-bbfg) for adult and pediatric patients one year of age and older with CHAPLE disease, known as CD55-deficient  
Via Benzinga
Exposures Product Safety
18 Analysts Have This to Say About Regeneron Pharmaceuticals
Via Benzinga
$100 Invested In This Stock 20 Years Ago Would Be Worth $5,400 Today
Via Benzinga
This Is What Whales Are Betting On Regeneron Pharmaceuticals
Via Benzinga
Why This Regeneron Approval 'Could Not Come Soon Enough' As Novartis Looms
The FDA signed off on Regeneron's high-dose Eylea about two months earlier than expected. 
Via Investor's Business Daily
Exposures Product Safety
FDA Approves Regeneron Pharmaceuticals' Higher Dose Of Eylea For Age-Related Blindness
The FDA approved Regeneron Pharmaceuticals Inc's (NASDAQ: REGN) approved Eylea HD (aflibercept) Injection 8 mg for wet age-related macular degeneration (wAMD), diabetic macular edema (DME),  
Via Benzinga
Exposures Product Safety
Is Regeneron Pharmaceuticals Still a Top Growth Stock?
The biotech's focus on innovation could be a boon for shareholders. 
Via The Motley Fool
Top Biotech Roivant, Formed By Vivek Ramaswamy, Reports Steep Losses, Light Sales
The company is working on a treatment for stomach diseases ulcerative colitis and Crohn's disease. 
Via Investor's Business Daily
Benzinga's 'Stock Whisper' Index: 5 Stocks Investors Are Secretly Monitoring But Not Talking About Yet
Investors are on the hunt for undervalued, underfollowed and emerging stocks, and retail traders have countless methods at their disposal to uncover new information. For some, this may be... 
Via Benzinga
Why the quality investor may take a look at NASDAQ:REGN.
REGENERON PHARMACEUTICALS (NASDAQ:REGN) may be suited for quality investing, we'll explore why in this article. 
Via Chartmill
This Is What Whales Are Betting On Regeneron Pharmaceuticals
Via Benzinga
(REGN) - Analyzing Regeneron Pharmaceuticals's Short Interest
Via Benzinga
The 7 Best Value Stocks to Buy in August
Stop chasing the hot flavors of the week and instead be friendly to your wallet with these ideas for best value stocks to buy. 
Via InvestorPlace
Regeneron's Aflibercept 8mg Shows Sustained Vision Gains At Two Years
Regeneron Pharmaceuticals Inc (NASDAQ: REGN) announced two-year (96 weeks) topline data from the pivotal PULSAR trial investigating aflibercept 8 mg in patients with wet age-related  
Via Benzinga
3 Top Biotech Stocks Defying the Bear Market
Biotech is still booming, if you pick the right biotech stocks. 
Via The Motley Fool
Health Care Company Regeneron Pharmaceuticals Announces Acquisition of Decibel Therapeutics
Via Benzinga
Decibel Therapeutics (DBTX) Stock Skyrockets 71% on Regeneron Deal
Decibel Therapeutics (DBTX) stock is soaring higher on Wednesday after signing a deal with Regeneron Pharmaceuticals (REGN). 
Via InvestorPlace
Decibel Therapeutics Stock Soars on Acquisition Deal - The Details
Regeneron Pharmaceuticals Inc (NASDAQ: REGN) has agreed to acquire Decibel Therapeutics Inc (NASDAQ: DBTX) at $4.00 per share with an additional contingent value right of up to $3.50 per share in cash... 
Via Benzinga
Regeneron Surmounts Its 200-Day Line On A Handy Second-Quarter Beat
Shares have been trapped below their 200-day moving average since late June. 
Via Investor's Business Daily
Earnings Scheduled For August 3, 2023
Companies Reporting Before The Bell • Cedar Fair (NYSE:FUN) is likely to report quarterly earnings at $1.10 per share on revenue of $512.74 million. 
Via Benzinga
Regeneron Pharmaceuticals Earnings Preview
Via Benzinga
3 AI Stocks You’ll Regret Not Buying Soon
AI will have a big impact on biotech, which could help with drug discovery and create opportunities for these top AI stocks to invest in. 
Via InvestorPlace
2 Top Stocks to Buy in August and Hold Forever
These companies won't disappoint long-term investors. 
Via The Motley Fool
Market Rally Under Pressure As Yields Soar; Amazon, ELF, Caterpillar Are Earnings Winners: Weekly Review
Amazon, ELF and CAT were earnings winners, but there were big losers too. 
Via Investor's Business Daily
Clorox, Boot Barn, Herbalife, Upwork And Other Big Stocks Moving Higher On Thursday
U.S. stocks traded lower, with the Dow Jones falling around 100 points on Thursday. Here are some big stocks recording gains in today’s session. Traeger, Inc. (NYSE: COOK) shares jumped 43.2% to $5.90... 
Via Benzinga
Why Is Regeneron Pharmaceuticals Moving Higher Today?
Regeneron Pharmaceuticals Inc (NASDAQ: REGN) earned second-quarter adjusted EPS of $10.24, up 5% Y/Y, beating the $9.92 Stre 
Via Benzinga
US Stock Futures Dip As Apple, Amazon Earnings Loom: Analyst Warns Of 'Perfectly Normal' 5% Pullback This Month
Stocks appear to be entrenched in an August swoon and it remains to be seen if big tech earnings provide a boost. 
Via Benzinga
< Previous 1 2
...
6 7 8 9 10 11 12 13 14
...
33 34 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.